TL;DR: The cannabis sector closed the week of July 7–11, 2026 on constructive footing, with MSOS posting back-to-back weekly gains as investor attention increasingly focuses on the Q2 2026 earnings calendar. Green Thumb Industries (GTBIF) and Curaleaf Holdings (CURLF) are scheduled to report in early August, and institutional positioning ahead of those releases appears to be driving current price action. The forward catalyst stack — rescheduling developments, earnings execution, and improving retail density metrics — supports a cautiously constructive stance into next week.
Market Analysis: MSOS Extends Weekly Win Streak
The AdvisorShares Pure US Cannabis ETF (MSOS) delivered its second consecutive week of gains through Friday’s close, a pattern that has historically preceded meaningful re-rating events in the sector. Friday’s session saw the ETF add approximately 2% as volume remained elevated relative to its 30-day average, suggesting institutional participation rather than retail-driven momentum.
The week’s performance was broad-based. Verano Holdings (VRNOF) outperformed on the basis of its Illinois retail density thesis and multi-state positioning, consolidating above key technical support. Tilray Brands (TLRY) held its recent gains, with the company’s multi-geography platform serving as a structural differentiator in the face of Canadian LP margin compression. Organigram Holdings (OGI) drew investor attention following confirmation of ongoing German medical market expansion and post-acquisition integration progress, positioning it as a potential beneficiary of European regulatory liberalization.
Innovative Industrial Properties (IIPR), the sector’s primary REIT exposure, continued its approach toward 52-week high territory. The underlying thesis is straightforward: a Schedule III reclassification event would structurally relieve the operating cost burden on IIPR’s tenant base, improving rent coverage ratios and reducing credit risk across the portfolio. That optionality is increasingly being priced into the stock.
Q2 Earnings Calendar: The Critical Phase Ahead
The Q2 2026 earnings season enters its final and most consequential phase over the next three weeks. Green Thumb Industries (GTBIF) is scheduled to report on August 4, followed by Curaleaf Holdings (CURLF) on August 5. Together, these two operators represent the largest combined revenue footprint among U.S. cannabis companies, and their results will set the tone for sector sentiment through the balance of the summer.
The key metrics to watch: Curaleaf’s revenue recovery trajectory following its strategic portfolio rationalization, Green Thumb’s Illinois same-store sales performance, and management commentary from both companies on any observable regulatory tailwinds at the state level. Forward guidance language — particularly any references to the federal regulatory environment — will likely move the tape more than the headline earnings numbers themselves.
For investors tracking this earnings cycle, our cannabis stock tracker provides current pricing, volume, and key dates for GTBIF, CURLF, VRNOF, TLRY, and the full MSO universe.
Regulatory and Market Context: Schedule III Backdrop Holds
The federal rescheduling backdrop remains the sector’s defining macro variable. The DEA’s proposed rule to move cannabis from Schedule I to Schedule III continues to work through the administrative review process, with a final rule still pending. While the timeline remains uncertain, the directional consensus among legal and policy observers has not shifted: reclassification is widely viewed as a matter of when, not if.
The practical implications of a Schedule III designation — most critically, the elimination of the 280E tax provision — would represent a step-change in operating cash flow for U.S. MSOs. Curaleaf, Green Thumb, Verano, and Cresco Labs collectively pay hundreds of millions in annual 280E-related taxes that would no longer apply under the new classification. That cash flow improvement would flow directly to the balance sheet, enabling debt reduction, capital reinvestment, or return-of-capital programs that are currently structurally unavailable to these operators.
Internationally, Germany’s evolving adult-use cannabis framework continues to create export opportunities for Canadian LPs with existing EU-GMP certification. OGI and TLRY are best-positioned among the names covered here to capture incremental German market share through 2026 and into 2027, and both management teams have signaled continued investment in European market access.
Forward Outlook: Week of July 14
Heading into the week of July 14, the technical setup for MSOS is modestly positive following two consecutive weeks of gains, but the sector is entering a traditionally lower-volume stretch between earnings cycles. Catalysts are event-driven rather than macro-driven; absent a surprise regulatory announcement or a pre-announcement from a major MSO, expect range-bound consolidation as the market awaits the August earnings cluster.
The constructive posture for patient capital remains intact. The combination of an improving earnings trajectory, deferred federal reform tailwinds, and emerging international demand creates a multi-layered investment thesis that does not depend on any single catalyst materializing on a fixed timeline. For cannabis investors with a 12–18 month horizon, current entry points in high-quality MSOs represent better risk-adjusted value than at virtually any point in the prior 12 months.
Sheeba M. is a cannabis market intelligence analyst at Weedstock. This content is for informational purposes only and does not constitute investment advice.